Modeling of Annual Treatment Costs and Health Outcomes of Antipsychotic Agents for Schizophrenic Populations

Josephine Mauskopf, PhD;

All News Press Releases Product Approvals and Launches

All Video Types AJMC TV Guidelines Insights OnLocation Payer Perspectives Peer Exchange Post Conference Perspectives Stakeholder Summit

Podcasts

Conference Coverage Conference Listing Post Conference Perspectives

All Journals The American Journal of Managed Care Population Health, Equity & Outcomes Evidence-Based Oncology About Supplements and Featured Publications Supplements and Featured Publications Issues Submit a Manuscript

Institute for Value-Based Medicine Patient-Centered Oncology Care

Interactive Tools Formulary Central Clinical Spotlight Microsites Sponsored Content

AJMC Staff Anniversary Seema Sonnad Award Strategic Alliance Partners

Dermatology Alopecia Atopic Dermatitis Psoriasis

Gastroenterology

Hematology ALL/AML CLL/SLL GVHD Hemophilia Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Non-Hodgkin Lymphoma Rare Blood

Hepatology Liver MASH

Immunology Allergy Autoimmune Inflammation Lupus Myasthenia Gravis Rheumatoid Arthritis

Infectious Disease COVID-19 HIV RSV Vaccines

Mental Health Major Depressive Disorder Sleep

Neurology Duchenne Muscular Dystrophy Epilepsy Multiple Sclerosis Parkinson Disease

Obesity

Oncology Breast Cancer Cholangiocarcinoma Colorectal Cancer Immuno-Oncology Liver Cancer Non–Small Cell Lung Cancer Ovarian Cancer Prostate Cancer Skin Cancer Small Cell Lung Cancer Soft Tissue Sarcoma

Ophthalmology

Pulmonology COPD Pulmonary Arterial Hypertension

Rare Disease Spinal Muscular Atrophy

Respiratory Asthma Pulmonary Fibrosis

Rheumatology

Women's Health

Biosimilars

Center on Health Equity & Access

Product Approvals and Launches

Technology

Value-Based Care

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Dermatology Alopecia Atopic Dermatitis Psoriasis

Gastroenterology

Hematology ALL/AML CLL/SLL GVHD Hemophilia Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Non-Hodgkin Lymphoma Rare Blood

Hepatology Liver MASH

Immunology Allergy Autoimmune Inflammation Lupus Myasthenia Gravis Rheumatoid Arthritis

Infectious Disease COVID-19 HIV RSV Vaccines

Mental Health Major Depressive Disorder Sleep

Neurology Duchenne Muscular Dystrophy Epilepsy Multiple Sclerosis Parkinson Disease

Obesity

Ophthalmology

Pulmonology COPD Pulmonary Arterial Hypertension

Rare Disease Spinal Muscular Atrophy

Respiratory Asthma Pulmonary Fibrosis

Rheumatology

Women's Health

Biosimilars

Center on Health Equity & Access

Product Approvals and Launches

Technology

Value-Based Care

Publication

Article

July 1, 1999

Supplements and Featured Publications

Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses

Volume5

Issue 10 Suppl

Modeling of Annual Treatment Costs and Health Outcomes of Antipsychotic Agents for Schizophrenic Populations

Author(s):

Josephine Mauskopf, PhD

Download PDF: Modeling of Annual Treatment Costs and Health Outcomes of Antipsychotic Agents for Schizophrenic Populations

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions

Modeling of Annual Treatment Costs and Health Outcomes of Antipsychotic Agents for Schizophrenic Populations

Newsletter